Q&A: Is Biomarker Testing Common in Early Stage NSCLC? – Targeted Therapies in Lung Cancer 2023

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins.

In this video, the panel discusses the importance of biomarker testing even in early stage NSCLC.

For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.

BenSound File Name: Sweet (BenSound.com)
BenSound License #: DSSHUIYGV4VQCETM

Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.